Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells (Q40371796)

19 September 2017

title

Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells (English)

1 reference

19 September 2017

1 reference

1 reference

X Li

1

1 reference

19 September 2017

R Luwor

2

1 reference

19 September 2017

Y Lu

3

1 reference

19 September 2017

K Liang

4

1 reference

19 September 2017

Z Fan

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

25

1 reference

19 September 2017

issue

4

1 reference

19 September 2017

page(s)

525-535

1 reference

Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Miltefosine in recurrent cutaneous breast cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Akt2, a novel functional link between p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in myogenesis

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

D-21266, a new heterocyclic alkylphospholipid with antitumour activity

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Alkylphosphocholines: a new class of membrane-active anticancer agents

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Akt1 regulates a JNK scaffold during excitotoxic apoptosis

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Submicromolar doses of alkyl-lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1209075

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209075

1 reference

Dimensions Publication ID

19 September 2017

1041455630

0 references

1 reference